Feedback
Make this your Home
Ind-Swift Laboratories > Company History > Pharmaceuticals > Company History of Ind-Swift Laboratories - BSE: 532305, NSE: INDSWFTLAB

Ind-Swift Laboratories

BSE: 532305  |  NSE: INDSWFTLAB  |  ISIN: INE915B01019  |  Pharmaceuticals

Company History - Ind-Swift Laboratories
YEAR                                              EVENTS
 
 2000 - The Company has developed a new drug ASTROVASTATIN which it
 would
              be launching in both domestic and international market.
 
           - The Company has alloted 7,43,300 -- five per cent
 non-cumulative, redeemable
              preference shares of Rs. 00 each at par to promoters
 group and associates.
 
           - The Unit Trust of India has picked up 5,00,000 No. of
 equity shares of the
              company which account for 4.98 per cent of the issued
 equity capital of the company.
 
           - The Company has entered into exclusive marketing
 agreements with some major
              international pharma companies.
 
           - Ind Swift Labs, a Chandigarh-based pharmaceutical
 company, has entered into 
             agreement with eight international pharmaceutical
 companies to source their 
            requirements for Clarithromycin, Fexofenadine,
 Roxithromycin and Candesartan 
            from the company.
 
 2002-Ind-Swift Laboratories Ltd has informed BSE that in the Board
 Meeting held on 30th July 2002 the Board has forfeited 1,75,900
 equity shares on which allotment money was due since 19th July,
 1997.
 
 2003
 the board has  approved the issue of 2322750 Equity shares upon
 conversion of preference shares into equity shares capital to the
 followings: -
 
 1. 1870375 equity shares to promoters at the rate of Rs 32/- per
 share 
 2. 452375 equity share to other bodies corporate at the rate of Rs
 32/- per share.
 
 -Ind-Swift Laboratories Ltd. has informed that the company has
 received an intimation from Ind-Swift Ltd., the promoter company that
 it has disinvested 386930 equity shares (2.48%) of the company and the
 present holding of Ind-Swift Limited is 22,57,970 equity shares of Rs.
 10/- each (14.46%).
 
 2004
 
 -Sets up subsidiary in US
 
 - Ind-Swift Laboratories shifts corporate and head office from SCO
 813, Shivalik Enclave, Nac, Manimajra, Chandigarh - 160101 to SCO
 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160101
 
 - Ind Swift Laboratories Ltd gets achievement award for the Best
 Performing Company in Category E by the Express Pharma Pulse for the
 year 2004.
 
 -Ind Swift Laboratories enters into long term agreements for supply
 of APIs
 
 -Ind Swift Laboratories wins Deloitte Fast 500 Award 2004 in HongKong
Source : Religare Technova

Stay on top of news
wherever you are
Follow news on a company or a topic
Set SMS alert
Newsletters

Daily Markets Newsletter

Sample   Subscribe Now

Daily Portfolio Update

  Subscribe Now

MF Newsletters

Sample   Subscribe Now

PF Newsletters

  Subscribe Now

Your Stocks
To SMS your queries to us Type YS < Your Query > SMS to 51818
Stocks to be discussed next:   GVK Power |  IFCI |  Kingfisher Air 
Chat with Experts
Steve Forbes

Editor-in-Chief , Forbes
(24 Nov- 18:30hrs) 

Upcoming Chat

Nov 30 | 12:00 PM
Hemant Luthra

Dec 01 | 11:00 AM
Harsh Mariwala

Dec 02 | 09:30 AM
Punita Kumar-Sinha

What the stars foretell

Bejan Daruwalla

Ganeshaspeaks: Market prediction for Nov 23

View all astrologers